This company is no longer active
IMARA Management
Management criteria checks 4/4
Key information
Rahul Ballal
Chief executive officer
US$2.0m
Total compensation
CEO salary percentage | 26.5% |
CEO tenure | 4.7yrs |
CEO ownership | 0.08% |
Management average tenure | 3.8yrs |
Board average tenure | 4.1yrs |
Recent management updates
Recent updates
Cancer drug developer Enliven Therapeutics and Imara to merge in all-stock deal
Oct 13Imara: Potential Liquidation
Sep 29We're Keeping An Eye On IMARA's (NASDAQ:IMRA) Cash Burn Rate
Jul 23We're Keeping An Eye On IMARA's (NASDAQ:IMRA) Cash Burn Rate
Sep 09IMARA (IMRA) EHA Investor Presentations - Slideshow
Jun 18Is IMARA (NASDAQ:IMRA) In A Good Position To Invest In Growth?
May 03Companies Like IMARA (NASDAQ:IMRA) Are In A Position To Invest In Growth
Jan 11Imara's sickle cell treatment shows promising action in mid-stage study
Jan 06Imara EPS in-line
Nov 05CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2022 | n/a | n/a | US$1m |
Sep 30 2022 | n/a | n/a | -US$45m |
Jun 30 2022 | n/a | n/a | -US$54m |
Mar 31 2022 | n/a | n/a | -US$56m |
Dec 31 2021 | US$2m | US$518k | -US$51m |
Sep 30 2021 | n/a | n/a | -US$49m |
Jun 30 2021 | n/a | n/a | -US$47m |
Mar 31 2021 | n/a | n/a | -US$44m |
Dec 31 2020 | US$626k | US$437k | -US$49m |
Sep 30 2020 | n/a | n/a | -US$45m |
Jun 30 2020 | n/a | n/a | -US$39m |
Mar 31 2020 | n/a | n/a | -US$34m |
Dec 31 2019 | US$2m | US$422k | -US$23m |
Sep 30 2019 | n/a | n/a | -US$19m |
Jun 30 2019 | n/a | n/a | -US$16m |
Mar 31 2019 | n/a | n/a | -US$13m |
Dec 31 2018 | US$938k | US$242k | -US$11m |
Compensation vs Market: Rahul's total compensation ($USD1.95M) is about average for companies of similar size in the US market ($USD1.64M).
Compensation vs Earnings: Rahul's compensation has been consistent with company performance over the past year.
CEO
Rahul Ballal (44 yo)
4.7yrs
Tenure
US$1,951,029
Compensation
Dr. Rahul D. Ballal, Ph D., is the Chief Executive Officer of Imara Inc. June 13, 2018. Dr. Rahul serves as Director of Agios Pharmaceuticals, Inc. since August 2022.Dr. Ballal is President and Director a...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President | 4.7yrs | US$1.95m | 0.084% $ 140.0k | |
CFO & COO | 3.8yrs | US$1.22m | 0.030% $ 50.3k | |
Senior VP of Legal & General Counsel | 2.8yrs | no data | no data |
3.8yrs
Average Tenure
Experienced Management: IMRA's management team is considered experienced (3.8 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President | 4.7yrs | US$1.95m | 0.084% $ 140.0k | |
Independent Director | 7.1yrs | US$82.17k | 0% $ 0 | |
Independent Chairman | 7.1yrs | US$120.59k | 0.87% $ 1.4m | |
Independent Director | 7.1yrs | US$90.65k | 0% $ 0 | |
Board Observer | no data | no data | no data | |
Independent Director | 3.9yrs | US$80.65k | 0% $ 0 | |
Independent Director | 3.9yrs | US$85.68k | 0% $ 0 | |
Board Observer | 4.1yrs | no data | no data | |
Independent Director | 1.7yrs | US$105.62k | 0% $ 0 | |
Independent Director | 2.8yrs | US$79.65k | 0% $ 0 | |
Board Observer | 4.1yrs | no data | no data | |
Board Observer | 4.1yrs | no data | no data |
4.1yrs
Average Tenure
53yo
Average Age
Experienced Board: IMRA's board of directors are considered experienced (4.1 years average tenure).
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2023/02/24 17:24 |
End of Day Share Price | 2023/02/23 00:00 |
Earnings | 2022/12/31 |
Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
IMARA Inc. is covered by 4 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Yigal Nochomovitz | Citigroup Inc |
Edward White | H.C. Wainwright & Co. |
Joseph Schwartz | Leerink Partners LLC |